Severe combined immune deficiency (SCID) patients with mutations in the IL-7 receptor (R) alpha chain or the gamma common subunit chain exhibit a severe block in early thymocyte development but have normal numbers of circulating B cells. This phenotype has been interpreted as evidence that human T and B-cell development have different IL-7 signaling requirements. We hypothesize that these apparent differences may reflect activation of different signaling pathways by IL-7, culminating in varying outcomes in survival/proliferation. Thus, the goal of the current study was to test this hypothesis using purified populations of normal human thymic and B-lineage lymphoid progenitors. CD34+ thymocytes (CD1a- multi-lineage lymphoid progenitors and CD1a+ early T-lineage progenitors representing 1–3% of total thymocytes) and CD34− thymocytes (CD4+/CD8+, CD4+/CD8−, and CD4−/CD8+ subpopulations) were purified using anti-CD34 magnetic beads. CD19+ B-lineage cells were purified with anti-CD19 magnetic beads from 4-wk cultures of cord blood CD34+ stem cells plated on MS-5 murine stromal cells. Flow cytometry revealed that the IL-7R was expressed on approx. 95% of CD34+ thymocytes, approx. 50% of CD34− thymocytes, and 30–50% of CD19+ B-lineage cells. Two to 3-day incubation with IL-7 induced proliferation of CD34+ thymocytes, and promoted survival (but not proliferation) of CD34- thymocytes and CD19+ B-lineage cells. Each population was stimulated with log concentrations of IL-7 for 1–20 min, lysed, and Western blotted. CD34+ thymocytes underwent robust phosphorylation (p) of STAT5, ERK1/2, AKT and the AKT substrate GSK3beta within 1 min and peaked at 5–10 min. Signaling was detected with as little as 10 pg/ml IL-7. CD34− thymocytes underwent comparable induction of pSTAT5, but no induction of pERK1/2, pAKT or pGSK3beta at up to 10 ng/ml IL-7. Incubation of CD34+ thymocytes with IL-7 for up to 3 days revealed IL-7 dose-dependent suppression of the cyclin-dependent kinase inhibitor p27Kip1, but no suppression of p27Kip1 was detected in IL-7 stimulated CD34− thymocytes. CD19+ cells exhibited IL-7 dose-dependent induction of pSTAT5, but showed only minimal induction of pERK1/2 and pGSK3beta (and only at 10 ng/ml IL-7), and did not suppress expression of p27Kip1. IL-7 induced pAKT and pERK1/2 in CD34+ thymocytes was blocked by the PI-3 kinase inhibitor LY294002 and the MEK inhibitor U0126, respectively. However, only LY294002 blocked proliferation. IL-7 promoted the expansion of CD19+ B-lineage cells cultured on MS-5 stromal cells, and expansion was blocked by LY294002 but not UO126. These collective results suggest that whereas induction of pSTAT5 is a constant outcome of IL-7 signaling in normal human lymphoid progenitors, activation of PI3-kinase/AKT and subsequent proliferation:
occurs in CD34+ thymocytes,
does not occur in CD34− thymocytes, and
occurs in CD19+ B-lineage cells; but potentially requires an additional cytokine stimulus derived from MS-5 stromal cells that cooperates with IL-7 to transduce a proliferative signal.
These IL-7 signaling outcomes may at least partially explain the differences in T and B lymphocyte development in SCID patients with mutations in the IL-7R alpha chain and the gamma common subunit chain.
Disclosure: No relevant conflicts of interest to declare.